Profile data is unavailable for this security.
About the company
Amplifon SpA is an Italy-based company active in the hearing care retail market. The Company provides personalized solutions and customer care to hearing-impaired people. It offers a wide range of services from diagnosing hearing difficulties, to fitting, servicing and maintaining hearing aids. The Company is organized in three geographical operating segments: Europe, Middle East and Africa - EMEA - (Italy, France, The Netherlands, Germany, the United Kingdom, Ireland, Spain, Portugal, Switzerland, Belgium, Luxemburg, Hungary, Egypt, Turkey, Poland and Israel), Americas (USA, Canada, Chile, Argentina, Ecuador, Colombia, Panama and Mexico) and Asia-Pacific (Australia, New Zealand, India and China).
- Revenue in EUR (TTM)2.29bn
- Net income in EUR160.70m
- Incorporated--
- Employees14.38k
- LocationAmplifon SpAVia Ripamonti 133MILANO 20141ItalyITA
- Phone+39 2574721
- Fax+39 257300033
- Websitehttps://www.amplifon.com/
Mergers & acquisitions
Acquired company | AMP:MIL since announced | Transaction value |
---|---|---|
Miracle-Ear Centers of Arkansas LLC | 14.67% | -- |
Las Davis Enterprises Inc | 14.67% | -- |
Hearing Pro Inc | 14.67% | -- |
Audical SRL | 14.16% | -- |
Living Sounds Hearing Centre | 19.05% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ambu A/S | 680.13m | 49.18m | 4.03bn | 4.75k | 92.59 | 6.08 | 40.89 | 5.92 | 1.38 | 1.38 | 19.09 | 21.05 | 0.7251 | 2.13 | 7.17 | 1,099,437.00 | 5.24 | 3.81 | 5.99 | 4.62 | 57.91 | 59.37 | 7.23 | 5.43 | 1.49 | 16.93 | 0.101 | 22.89 | 7.45 | 12.88 | 80.65 | -13.00 | 6.67 | -- |
Getinge AB | 2.77bn | 196.54m | 4.08bn | 11.86k | 22.26 | 1.57 | 11.98 | 1.47 | 8.39 | 8.39 | 118.22 | 118.80 | 0.6001 | 2.53 | 6.79 | 2,742,908.00 | 4.29 | 5.31 | 5.56 | 6.98 | 45.37 | 47.83 | 7.15 | 8.69 | 0.7569 | 11.47 | 0.2035 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
GN Store Nord A/S | 2.44bn | 71.83m | 4.38bn | 7.05k | 58.53 | 3.16 | 14.39 | 1.79 | 3.70 | 3.70 | 127.04 | 68.44 | 0.6139 | 3.00 | 4.73 | 2,541,382.00 | 1.94 | 4.91 | 3.22 | 7.44 | 50.50 | 53.29 | 3.16 | 6.82 | 0.4118 | 2.50 | 0.5582 | 36.84 | -3.03 | 11.30 | -55.38 | -28.74 | 7.53 | -- |
SCHOTT Pharma AG & Co KgaA | 905.64m | 158.11m | 4.63bn | 4.65k | 29.30 | 6.44 | 22.38 | 5.12 | 1.05 | 1.05 | 6.01 | 4.78 | -- | -- | -- | 194,928.30 | -- | -- | -- | -- | 35.23 | -- | 17.48 | -- | 1.08 | -- | 0.094 | -- | 9.43 | -- | 21.11 | -- | -- | -- |
Ypsomed Holding AG | 513.14m | 73.06m | 4.65bn | 2.20k | 63.63 | 8.04 | 30.86 | 9.07 | 5.31 | 5.31 | 37.31 | 42.03 | 0.5888 | 4.92 | 5.75 | 247,016.00 | 8.38 | 4.44 | 12.70 | 6.77 | 32.04 | 26.95 | 14.24 | 6.87 | 0.5577 | 30.61 | 0.2614 | 18.54 | 7.02 | 1.31 | 121.92 | -0.3034 | 20.32 | -1.47 |
ConvaTec Group PLC | 1.98bn | 120.49m | 6.06bn | 10.13k | 50.40 | 3.87 | 19.00 | 3.06 | 0.05 | 0.05 | 0.8214 | 0.6499 | 0.5865 | 2.57 | 6.14 | 166,453.20 | 3.57 | 2.36 | 4.18 | 2.73 | 56.04 | 55.03 | 6.08 | 4.34 | 0.8835 | 2.65 | 0.4367 | 127.29 | 3.37 | 3.18 | 107.15 | -6.93 | 12.37 | 31.41 |
Amplifon SpA | 2.29bn | 160.70m | 7.51bn | 14.38k | 46.48 | 6.60 | 17.20 | 3.27 | 0.7137 | 0.7137 | 10.16 | 5.03 | 0.6183 | 20.30 | 10.56 | 159,464.60 | 4.34 | 4.31 | 6.35 | 5.81 | 23.78 | 59.01 | 7.03 | 7.28 | 0.4667 | 5.98 | 0.5814 | 34.26 | 6.65 | 10.66 | -12.21 | 9.08 | 12.68 | 15.68 |
Carl Zeiss Meditec AG | 2.06bn | 261.22m | 8.31bn | 4.95k | 31.74 | 3.97 | -- | 4.03 | 2.93 | 2.93 | 23.12 | 23.41 | 0.7296 | 1.81 | 5.57 | 427,523.50 | 9.27 | 9.56 | 11.33 | 11.72 | 56.32 | 57.84 | 12.70 | 13.15 | 2.41 | -- | 0.1018 | 34.47 | 9.80 | 10.28 | -1.20 | 18.09 | 26.79 | 14.87 |
Demant A/S | 3.01bn | 342.01m | 9.93bn | 21.62k | 29.29 | 7.98 | -- | 3.30 | 11.44 | 8.05 | 100.58 | 41.97 | 0.7431 | 2.05 | 5.88 | 1,037,923.00 | 8.46 | 8.27 | 12.20 | 13.23 | 73.72 | 74.14 | 11.38 | 11.34 | 0.9529 | 5.98 | 0.6075 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
Smith & Nephew plc | 5.13bn | 243.19m | 10.47bn | 18.45k | 42.99 | 2.16 | 11.97 | 2.04 | 0.2371 | 0.2371 | 5.00 | 4.71 | 0.5562 | 0.7522 | 4.33 | 236,662.50 | 2.64 | 4.10 | 3.29 | 4.99 | 68.82 | 71.39 | 4.74 | 8.02 | 0.72 | 4.84 | 0.3715 | 79.59 | 6.40 | 2.50 | 17.94 | -16.88 | 4.24 | 1.85 |
Holder | Shares | % Held |
---|---|---|
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 5.99m | 2.65% |
Comgest SAas of 31 Jan 2024 | 5.07m | 2.24% |
The Vanguard Group, Inc.as of 09 May 2024 | 4.58m | 2.02% |
Allianz Global Investors GmbHas of 30 Apr 2024 | 2.86m | 1.27% |
T. Rowe Price International Ltd.as of 31 Mar 2024 | 2.61m | 1.15% |
BlackRock Fund Advisorsas of 09 May 2024 | 2.16m | 0.95% |
Norges Bank Investment Managementas of 21 Apr 2023 | 2.06m | 0.91% |
Cr�dit Mutuel Asset Management SAas of 31 Mar 2023 | 1.99m | 0.88% |
BlackRock Advisors (UK) Ltd.as of 09 May 2024 | 1.76m | 0.78% |
Amundi Asset Management SA (Investment Management)as of 08 May 2024 | 1.58m | 0.70% |